BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 25832692)

  • 1. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
    Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans.
    Chang JH; Lim Joon D; Lee ST; Gong SJ; Anderson NJ; Scott AM; Davis ID; Clouston D; Bolton D; Hamilton CS; Khoo V
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e691-6. PubMed ID: 22658218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.
    Murray LJ; Lilley J; Thompson CM; Cosgrove V; Mason J; Sykes J; Franks K; Sebag-Montefiore D; Henry AM
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):406-15. PubMed ID: 24685447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric and radiobiological consequences of computed tomography-guided adaptive strategies for intensity modulated radiation therapy of the prostate.
    Battista JJ; Johnson C; Turnbull D; Kempe J; Bzdusek K; Van Dyk J; Bauman G
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):874-80. PubMed ID: 23978708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy.
    Pasquier D; Cavillon F; Lacornerie T; Touzeau C; Tresch E; Lartigau E
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):549-54. PubMed ID: 22677369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study.
    Ost P; Speleers B; De Meerleer G; De Neve W; Fonteyne V; Villeirs G; De Gersem W
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):920-6. PubMed ID: 20675077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost.
    Pinkawa M; Attieh C; Piroth MD; Holy R; Nussen S; Klotz J; Hawickhorst R; Schäfer W; Eble MJ
    Radiother Oncol; 2009 Nov; 93(2):213-9. PubMed ID: 19717197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
    van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Thomas L; Kantz S; Hung A; Monaco D; Gaertner FC; Essler M; Strunk H; Laub W; Bundschuh RA
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1170-1178. PubMed ID: 29468311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer.
    Davidson MT; Blake SJ; Batchelar DL; Cheung P; Mah K
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1550-8. PubMed ID: 21543164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.
    Widesott L; Pierelli A; Fiorino C; Lomax AJ; Amichetti M; Cozzarini C; Soukup M; Schneider R; Hug E; Di Muzio N; Calandrino R; Schwarz M
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1589-600. PubMed ID: 21167651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity modulated proton and photon therapy for early prostate cancer with or without transperineal injection of a polyethylen glycol spacer: a treatment planning comparison study.
    Weber DC; Zilli T; Vallee JP; Rouzaud M; Miralbell R; Cozzi L
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e311-8. PubMed ID: 22999271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
    Stanic S; Mathai M; Cui J; Purdy JA; Valicenti RK
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1897-902. PubMed ID: 21536391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of androgen deprivation therapy on intraprostatic tumour volume identified on
    Chan J; Carver A; Brunt JN; Vinjamuri S; Syndikus I
    Br J Radiol; 2017 Mar; 90(1071):20160818. PubMed ID: 27993093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
    Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal dose escalation for prostate cancer using
    Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
    Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost.
    Pinkawa M; Holy R; Piroth MD; Klotz J; Nussen S; Krohn T; Mottaghy FM; Weibrecht M; Eble MJ
    Strahlenther Onkol; 2010 Nov; 186(11):600-6. PubMed ID: 20936457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
    Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
    Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using
    Zamboglou C; Sachpazidis I; Koubar K; Drendel V; Wiehle R; Kirste S; Mix M; Schiller F; Mavroidis P; Meyer PT; Werner M; Grosu AL; Baltas D
    Radiother Oncol; 2017 Jun; 123(3):472-477. PubMed ID: 28499607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
    Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.